RNA Analysis/ Transcriptomics Market Report 2025

This RNA Analysis/ Transcriptomics report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The RNA analysis/ transcriptomics market size has grown rapidly in recent years. It will grow from $7.72 billion in 2024 to $8.8 billion in 2025 at a compound annual growth rate (CAGR) of 14.1%. The growth in the historic period can be attributed to cancer research and precision medicine, drug discovery and development, infectious disease diagnostics, personalized medicine, academic and government funding, growing applications in agriculture.

The RNA analysis/ transcriptomics market size is expected to see rapid growth in the next few years. It will grow to $16.54 billion in 2029 at a compound annual growth rate (CAGR) of 17.1%. The growth in the forecast period can be attributed to single-cell rna sequencing applications, integration of rna analysis in clinical diagnostics, rna-basedTherapies and vaccines, bioinformatics and data analysis tools, biomarker discovery and validation. Major trends in the forecast period include spatial transcriptomics and in situ rna analysis, long-read rna sequencing technologies, rna editing and modification analysis, integration of ai in rna data analysis, rna therapeutics for rare diseases, rna-based liquid biopsy for cancer detection.

The growth of the RNA analysis/transcriptomics market is anticipated to be driven by the increasing demand for personalized medicine. Personalized medicine involves tailoring medical treatment to the unique characteristics of each patient. The RNA-Seq technology is well-suited to manage the substantial clinical workload associated with implementing personalized clinical care practices and processes. The Personalized Medicine Coalition (PMC) reported in October 2022 that there will be over 75,000 genetic testing products and 300 personalized medicines available for various conditions such as multiple types of cancer, genetic rare diseases, and chronic and infectious diseases. This surge in demand for personalized medicines is a key factor propelling the growth of the RNA analysis market.

The growing prevalence of chronic diseases is expected to drive the expansion of the RNA analysis/transcriptomics market in the future. Chronic diseases are defined as conditions lasting a year or longer that hinder daily activities and necessitate ongoing medical care. The use of RNA analysis and transcriptomics in chronic disease research enhances understanding of disease mechanisms, leads to better diagnostics, and facilitates the development of more targeted and personalized therapeutic interventions. For instance, in September 2022, the World Health Organization, a specialized agency of the United Nations based in Switzerland, reported that 41 million deaths each year, accounting for 74% of deaths caused by non-communicable diseases (NCDs) or chronic diseases, occur globally. Among these, there were 17.9 million deaths from cardiovascular diseases, 9.3 million from cancer, 4.1 million from chronic respiratory diseases, and 2 million from diabetes. Thus, the rising incidence of chronic diseases is propelling the growth of the RNA analysis/transcriptomics market.

An emerging trend in the RNA analysis/transcriptomics market is the focus on technological advancements and innovations in RNA analysis. Next-generation sequencing (NGS) and RNA interference (RNAi) are among the technologies contributing to improved precision and accuracy in analyzing transcriptional activity. Illumina's development of Next-generation sequencing, for example, has proven successful in fragmenting DNA/RNA, sequencing libraries, and reassembling them, enhancing genomic sequence analysis.

Major companies in the RNA analysis/transcriptomics market are increasingly emphasizing the introduction of innovative portfolios to gain a competitive advantage. Twist Bioscience Corporation, in May 2023, launched a comprehensive RNA sequencing tools portfolio, including specific target enrichment capabilities for RNA and whole transcriptome sequencing. The portfolio comprises products such as the Twist RNA Exome, Twist RNA Library Prep Kit, and Twist Ribosomal RNA (rRNA) and Hemoglobin (Globin) Depletion Kit, offering complete workflows for analyzing mRNA protein coding sequences, custom targets, and total RNA.

Strategic partnerships and collaborations are a significant focus for major companies in the RNA analysis/transcriptomics market. These partnerships often involve integrating expertise in RNA library preparation kits, combining the knowledge and resources of different organizations. For instance, Singular Genomics Systems Inc. collaborated with Lexogen in January 2022 to demonstrate the compatibility of the G4 sequencing platform with Lexogen's products for RNA research. This partnership aims to provide customers with a seamless integration of the G4 into existing Next-Generation Sequencing (NGS) workflows.

Major companies operating in the RNA analysis/ transcriptomics market include Affymetrix Inc., Agilent Technologies Inc., Bio-Rad Laboratories Inc., GE Healthcare, Illumina Inc., QIAGEN N.V., F. Hoffmann-La Roche Ltd., Sigma-Aldrich Corporation, Thermo Fisher Scientific Inc., Fluidigm Corporation, Promega Corporation, bioMérieux S.A., CD Genomics Inc., Eurofins Scientific SE, Merck KGaA, Pacific Biosciences of California Inc., Danaher Corporation, Genewiz Inc., Oxford Nanopore Technologies Ltd., BGI Group, Genotypic Technology Pvt. Ltd., MedGenome Labs Pvt. Ltd., Xcelris Labs Ltd., Ocimum Biosolutions Ltd., Strand Life Sciences Pvt. Ltd., SciGenom Labs Pvt. Ltd., Oncocyte Corporation, Tempus Labs Inc., ArcherDX Inc., HTG Molecular Diagnostics Inc.

North America was the largest region in the RNA analysis/transcriptomics market in 2024. This region is expected to be the fastest-growing region in the forecast period. The regions covered in the RNA analysis/ transcriptomics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the RNA analysis/ transcriptomics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Transcriptomics, also known as RNA analysis, is the study of the transcriptome under specific circumstances, environmental conditions, or within specific cells using high-throughput methods.

The main product categories in the RNA analysis/transcriptomics market include reagents/consumables, instruments, and software. These products find applications in various fields, such as clinical diagnostics, drug discovery, toxicogenomics, comparative transcriptomics, and RNA interference. The major technologies involved in RNA analysis/transcriptomics are microarrays, sequencing, polymerase chain reaction, and RNA interference. In clinical diagnostics, RNA analysis is employed to detect different RNA species, pathogen RNA, splice variants, and other elements crucial for disease diagnosis.

The RNA analysis/ transcriptomics market research report is one of a series of new reports that provides RNA analysis/ transcriptomics market statistics, including RNA analysis/ transcriptomics industry global market size, regional shares, competitors with a RNA analysis/ transcriptomics market share, detailed RNA analysis/ transcriptomics market segments, market trends and opportunities, and any further data you may need to thrive in the RNA analysis/ transcriptomics industry. This RNA analysis/ transcriptomics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The RNA analysis/ transcriptomics market includes revenues earned by entities by providing services such as Whole-Genome Sequencing, Whole-Exome Sequencing, Targeted Sequencing, Microarray Analysis, Sanger Sequencing services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.